Kadimastem’s attempt to vault onto Nasdaq is picking up momentum, with shareholders signing off on a merger with NLS Pharmaceutics that would enable the cell therapy developer to recover from last ...
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...